Tucatinib Instructions for Use

Tucatinib is a new type of targeted drug, its main indications are the following types of cancer patients:

1.Metastatic breast cancer: This drug is approved for use in combination with trastuzumab and capecitabine, specifically for adults with advanced breast cancer that is HER2 positive, unresectable, or has metastasized (including brain metastases). These patients often have continued disease progression despite receiving one or more anti-HER2-based regimens. Therefore, the use of tucatinib provides a new treatment option for these patients, helping to delay disease progression and improve quality of life.

2.Unresectable or metastatic colorectal cancer: Tucatinib can be used in combination with trastuzumab for adult patients with RAS wild-type and HER2-positive unresectable or metastatic colorectal cancer. Especially after patients have received chemotherapy regimens including fluoropyrimidine, oxaliplatin, and irinotecan, if the disease still progresses, the application of tucatinib will become an important treatment strategy.

Mechanism of action

Tucatinib is an oral small molecule tyrosine kinase inhibitor that selectively acts on the HER2 receptor. HER2The receptor is a transmembrane receptor tyrosine kinase highly expressed in certain types of breast cancer cells. By inhibiting the kinase activity of the HER2 receptor, tucatinib can effectively block its downstream signaling pathways, thereby inhibiting the proliferation and metastasis of tumor cells. Specifically, tucatinib can significantly reduce the phosphorylation and proliferative activities of HER2 and its downstream effector Akt. Compared with other receptors, such as EGFR, tucatinib's selective inhibitory effect on HER2 is more obvious. This feature reduces side effects and toxic reactions caused by inhibiting other receptors, making it more advantageous in clinical applications.

Medication method

Each time300mg twice daily, administered orally.

side effects

1.Gastrointestinal reactions: Common side effects include diarrhea, nausea, vomiting and abdominal pain. Among them, diarrhea is the most common reaction and may affect the patient's quality of life to a certain extent. During treatment, patients should maintain adequate fluid intake and use antidiarrheal medications when necessary to prevent dehydration and related complications.

2.Abnormal liver function: Some patients may experience an increase in liver function indicators, such as abnormal aminotransferase levels, when taking tucatinib. Therefore, liver function indicators need to be monitored regularly during treatment in order to adjust drug dosage or interrupt treatment in a timely manner to avoid serious liver damage.

3.Skin reactions: rashes, dryness, itching and skin inflammation may also occur. Hand-foot syndrome, characterized by redness, swelling, pain, or peeling of the skin on the palms and soles, is also a possible side effect. For these skin reactions, patients should pay attention to moisturizing, avoid prolonged rubbing of the affected area, and seek medical advice if necessary.

4.Fatigue: Many patients may feel tired and weak while taking tucatinib, and this fatigue will cause certain interference in daily life. Proper rest and moderate exercise can help relieve this symptom.

5.Other side effects: such as headache, joint pain, muscle pain, etc. Most of these side effects are temporary and usually disappear after stopping the drug.

Warnings and precautions

Special attention should be paid to the use of tucatinib, which should be contraindicated in patients who are allergic to the drug or its excipients. In addition, patients with severe liver dysfunction should not use this drug, and liver function should be monitored regularly during medication to ensure safety.

drug interactions

The use of tucatinib may be affected by other drugs, especially those that are strongCYP3A4 inhibitors (such as clarithromycin, etc.). Concomitant use of such drugs may increase tucatinib plasma concentrations, thereby increasing the risk of adverse effects. Therefore, careful evaluation and possible dose adjustment are required during coadministration.

In addition, when taken together with some HIV and hepatitis C drugs (such as ritonavir, etc.), it may increase toxicity and cause severe liver damage. In terms of food, although tucatinib can be taken with food, it should be avoided with high-fat foods to avoid affecting the absorption and metabolism of the drug.

Medication for special populations

Tucatinib is contraindicated in pregnant and lactating women due to potential harm to the fetus.

References:

https://www.drugs.com/monograph/tucatinib.html